Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects (Q44104205)

29 November 2017

Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects (English)

1 reference

29 November 2017

0 references

5

Giovanni De Pergola

1 reference

29 November 2017

Nicola Pannacciulli

1

1 reference

29 November 2017

Vito De Mitrio

series ordinal

2

1 reference

29 November 2017

Renato Marino

series ordinal

3

1 reference

29 November 2017

Riccardo Giorgino

series ordinal

4

1 reference

29 November 2017

1 August 2002

1 reference

29 November 2017

1 reference

29 November 2017

10

1 reference

29 November 2017

8

1 reference

29 November 2017

717-725

1 reference

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk)

29 November 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Endogenous tissue-type plasminogen activator and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Fat cell function and fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Gender differences in the relationships between plasma plasminogen activator inhibitor-1 activity and factors linked to the insulin resistance syndrome in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Hyperglycemia induces PAI-1 gene expression in adipose tissue by activation of the hexosamine biosynthetic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

PAI-1 produced ex vivo by human adipose tissue is relevant to PAI-1 blood level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Prevalence of coronary heart disease in subjects with normal and impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a biethnic Colorado population. The San Luis Valley Diabetes Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Impaired glucose tolerance, Type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Subcutaneous adipose tissue expression of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic and Type 2 diabetic subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Insulin continues to induce plasminogen activator inhibitor 1 gene expression in insulin-resistant mice and adipocytes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Cardiovascular risk factors and impaired glucose tolerance: the San Luis Valley Diabetes Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Asymptomatic hyperglycemia and atherosclerotic vascular disease in the elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

inferred from DOI database lookup

7 January 2021

based on heuristic

Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity.

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.98

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/OBY.2002.98

1 reference

29 November 2017

1 reference